Global Medical REIT price target raised to $12.50 from $11 at Compass Point

Compass Point analyst Merrill Ross raised the firm’s price target on Global Medical REIT to $12.50 from $11 and keeps a Buy rating on the shares after the company reported Q2 results that were in line with the firm’s estimate. A strategy of recycling capital during a period of interest rate volatility “involves a significant degree of execution risk,” but the firm has confidence in Global Medical’s management team, the analyst tells investors.